Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients (Pts) With Advanced Non-Small-Cell Lung Cancer (NSCLC)

摘要

The programmed death-1 (PD-1) pathway is important in T-cell activation, and its role in NSCLC requires further study. Expression of PD-1 on tumor infiltrating lymphocytes decreases cytokine production and effector function. The expression of PD-L1 has been noted in NSCLC. Increased PD-1 expression on tumor cells is correlated with an increased number of tumor-infiltrating lymphocytes in the same region.